TABLE 2 | Public–private partnerships and their partners
From the following article:
Can open-source R&D reinvigorate drug research?
Bernard Munos
Nature Reviews Drug Discovery 5, 723-729 (September 2006)
doi:10.1038/nrd2131
| Project | Industry partner | University/public health partner | Other PPP |
|---|---|---|---|
CDC, Centers for Disease Control and Prevention; DNDi, Drugs for Neglected Diseases Initiative; NIH, National Institutes of Health; TDR, UNICEF–UNDP–World Bank–WHO Special Programme for Research and Training in Tropical Diseases. | |||
| Medicines for Malaria Venture | |||
| Improved 4-aminoquinoline | GlaxoSmithKline | University of Liverpool | |
| Farnesyl transferase inhibitors | Bristol-Myers Squibb | University of Washington | |
| Manzamine derivatives | University of Mississipi | ||
| Cysteine protease inhibitors | GlaxoSmithKline | UCSF | |
| Fatty acid biosynthesis inhibition | Texas A&M, A. Einstein, Jacobus | ||
| Pyridone | GlaxoSmithKline | ||
| New di-cationic molecules | Immtech | University of North Carolina | |
| Dihydrofolate reductase inhibition | Biotec Thailand | ||
| Artesunate derivatives | GlaxoSmithKline, Shin Poong | TDR, DNDi | |
| Artemisone | Bayer | University of Hong Kong | |
| Synthetic peroxide | Ranbaxy | University of Nebraska | |
| Intravenous artesunate | Walter Reed | ||
| Coartem in infants | Novartis | TDR | |
| TB Alliance | |||
| Pyridones and quinolizines | Taejon, Yonsei | ||
| Isoniazid analogue | Wellesley College | ||
| PA-824 | NIH, Johns Hopkins | ||
| Mocifloxaxin | Bayer | CDC, Johns Hopkins | |
| Institute for One World Health | |||
| Paromomycin | TDR | ||
| Azole | Yale | ||
| TDR | |||
| Miltefosine | Zentaris | ||
| Oral eflornithine | Aventis | ||
Download file
If the slide opens in your browser, select "File > Save As" to save it.
